ArticleHepatology international2025

Efficacy and safety of atezolizumab and bevacizumab with or without TACE as first-line therapy for unresectable HCC: a multicenter cohort study.

Ningning Zhang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.